AZTR — Azitra, Inc.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: New York Stock Exchange American
- Employees: 12
- Website: https://azitrainc.com
Latest SEC filings for AZTR
- 424B5 — 2026-09-28
- SCHEDULE 13G — 2026-08-14
- SCHEDULE 13G — 2026-06-22
- EFFECT — 2026-06-03
- 8-K — 2026-05-27
- S-1 — 2026-05-21
- 10-Q — 2026-05-13
- 8-K — 2026-05-13
- 8-K — 2026-03-23
- 8-K — 2026-03-13
Latest AZTR news
- — Azitra announces 1-for-10 reverse stock split (seekingalpha_market)
- — Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance (prnewswire.com)
Educational tool only — not investment advice.